Parametrica Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Parametrica Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-923	Closed	-$218K	–	234
2020 Q4	$218K	Buy	+923	New	+$212K	0.13%	146
2019 Q1	–	Sell	-1,636	Closed	-$271K	–	315
2018 Q4	$271K	Buy	+1,636	New	+$283K	0.33%	150
2017 Q4	–	Sell	-1,954	Closed	-$297K	–	486
2017 Q3	$297K	Buy	+1,954	New	+$294K	0.13%	193
2017 Q2	–	Sell	-8,624	Closed	-$943K	–	382
2017 Q1	$943K	Buy	+8,624	New	+$759K	0.98%	3
2016 Q4	–	Sell	-5,302	Closed	-$462K	–	272
2016 Q3	$462K	Buy	+5,302	New	+$501K	1.27%	9
2016 Q2	–	Sell	-5,083	Closed	-$404K	–	240
2016 Q1	$404K	Buy	+5,083	New	+$460K	1.45%	14

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Parametrica Management's VRTX Position: Q1 2021 in Review

Parametrica Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2021, closing a stake of 923 shares — an estimated $218K sold.

Parametrica Management first reported a position in VRTX in Q1 2016 and held it in 6 quarters. The position peaked at $943K in Q1 2017. 1,000 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

Parametrica Management reported no remaining Vertex Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Parametrica Management sold 923 Vertex Pharmaceuticals shares in Q1 2021, an estimated $218K.
Parametrica Management first reported a position in Vertex Pharmaceuticals in Q1 2016 and held it in 6 quarters.
Parametrica Management's Vertex Pharmaceuticals position peaked at $943K in Q1 2017.
1,000 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Parametrica Management's 13F filing for Q1 2021, filed 14 May 2021.